Hepatic Disease in HIV-Infected Patients

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 9/4/18 (What's New)

Summary

  • Improving systemic insulin resistance may be beneficial but is not sufficient to prevent progression of fatty liver disease
  • US and European guidelines support reserving the use of pharmacotherapy for treatment of insulin resistance to patients with NASH or fibrosis[AASLD NAFLD; EASL NAFLD]

Action required